Nanocarriers Market Report 2026

The nanocarriers market size has grown rapidly in recent years. It will grow from $11.61 billion in 2025 to $13.74 billion in 2026 at a compound annual growth rate (CAGR) of 18.4%. The growth in the historic period can be attributed to advancements in nanotechnology research, increasing pharmaceutical R&D investments, growing need for improved drug bioavailability, early adoption of nanoparticle-based therapeutics, expansion of academic and clinical research.

The nanocarriers market size is expected to see rapid growth in the next few years. It will grow to $26.74 billion in 2030 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to increasing demand for personalized therapeutics, rising investments in advanced drug delivery systems, expansion of nanocarrier applications in oncology and gene therapy, growing focus on reducing drug side effects, continued innovation in nanoscale engineering. Major trends in the forecast period include increasing development of targeted drug delivery platforms, growing adoption of lipid and polymeric nanocarriers, rising focus on controlled and sustained release systems, expansion of nanocarriers in gene and vaccine delivery, enhanced integration with precision medicine approaches.

The growing demand for personalized medicines is set to boost the nanocarriers market in the future. Personalized medicine involves customizing medical treatments to match each patient's unique traits, especially through genetic, biomarker, and molecular data. Focus on personalized medicine is increasing because it enables physicians to adapt cancer therapies to a patient's genetic makeup, enhancing outcomes and minimizing avoidable side effects. Nanocarriers support personalized medicine by delivering drugs accurately to targets specific to the patient, regulating release, boosting bioavailability, and enabling customized combination treatments aligned with individual biology. For example, in February 2024, the Personalized Medicine Coalition - a US-based nonprofit - reported that the United States Food and Drug Administration (FDA) approved 16 new personalized therapies for rare diseases in 2023, up significantly from only six in 2022. Thus, the surging demand for personalized medicines is fueling expansion in the nanocarriers market.

Major companies in the nanocarriers market are focusing on advanced formulations, such as lipid nanoparticle technologies, to boost targeted drug delivery and therapeutic effectiveness. These technologies involve nanoscale, lipid-based carriers that transport drugs or genetic therapies to specific cells or tissues in a safe and efficient manner. For example, in July 2023, Cytiva - a US-based biotechnology firm - introduced the NanoAssemblr commercial formulation system, a fully automated, single-use platform for complete clinical and commercial production of lipid nanoparticle (LNP) medicines. Powered by Cytiva’s NxGen technology, this system delivers precise, reproducible mixing to maintain uniform quality from research through large-scale cGMP manufacturing. Its single-use fluid path minimizes cross-contamination risks and enables efficient multi-product production within a single facility. Additionally, the platform includes user-friendly software that meets regulatory requirements, automates processes, and supports electronic batch records to simplify the creation of genomic medicines like mRNA vaccines, gene therapies, and cancer vaccines.

In August 2024, VION Biosciences LLC, a US-based life science platform company, acquired Echelon Biosciences Inc., a US-based biotechnology company that manufactures lipid nanoparticles (LNPs) - a crucial nanocarrier for mRNA-based therapies - for an undisclosed amount, aiming to better serve customers developing diverse mRNA and gene-based biotherapeutics by expanding its portfolio, bolstering drug discovery and preclinical capabilities, and entering the drug manufacturing space.

Major companies operating in the nanocarriers market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi S.A., Novartis AG, Bristol-Myers Squibb Company, Amgen Inc., Evonik Industries AG, Matinas BioPharma Holdings Inc., Luye Pharma Group Ltd., Ascendia Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Nanobiotix S.A., Polymun Scientific Immunbiologische Forschung GmbH, ReCode Therapeutics Inc., Celsion Corporation, Starpharma Holdings Limited, EnGeneIC Ltd., Acuitas Therapeutics Inc., Altamira Therapeutics Ltd., Nanexa AB.

North America was the largest region in the nanocarriers market in 2025. The regions covered in the nanocarriers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nanocarriers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the nanocarriers market by increasing costs of imported nanomaterials, specialized polymers, lipids, laboratory equipment, and precision manufacturing tools required for nanoscale formulation. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on imported high-purity inputs, while Asia-Pacific faces higher costs for export-oriented nanomaterial production. These tariffs are increasing R&D and production expenses and slowing commercialization timelines. However, they are also encouraging domestic nanomaterial manufacturing, regional research collaboration, and localized scale-up of nanocarrier production.

The nanocarriers market research report is one of a series of new reports that provides nanocarriers market statistics, including nanocarriers industry global market size, regional shares, competitors with a nanocarriers market share, detailed nanocarriers market segments, market trends and opportunities, and any further data you may need to thrive in the nanocarriers industry. This nanocarriers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nanocarriers are nanoscale delivery platforms designed to transport drugs, genes, or other therapeutic agents with precise targeting, delivering them directly to specific cells or tissues in the body. These sophisticated systems enhance the stability and bioavailability of treatments, enable controlled and prolonged release, and reduce side effects by limiting exposure to non-target healthy tissues.

The primary categories of nanocarriers include polymeric nanocarriers, lipid-based nanocarriers, inorganic nanocarriers, and additional types. Polymeric nanocarriers consist of nanoscale systems based on polymers, engineered to transport drugs or therapeutic agents effectively to specific locations within the body. They find use in areas like drug delivery, diagnostics, vaccines, gene therapy, and more, catering to end-users such as pharmaceutical and biotechnology firms, hospitals and clinics, research institutions, and others.

The nanocarriers market consists of sales of polymeric nanoparticles, nanocrystals, carbon nanotubes, exosomes, and quantum dots. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.